{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 457152625
| IUPAC_name = (–)-2-[(''R'')-(diphenylmethyl)sulfinyl]acetamide
| image = Armodafinil.svg
| width = 150px

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|monograph|armodafinil}}
| MedlinePlus = a602016
| pregnancy_category = C
| legal_US = Schedule IV
| legal_status = Rx-only
| routes_of_administration = 口服

<!--Pharmacokinetic data-->
| metabolism = 肝脏，包含[[CYP3A4|CYP3A4]]和其他途径
| elimination_half-life = 12-15 小时
| excretion = 尿液（作为代谢物）

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 112111-43-0
| ATC_prefix = N06
| ATC_suffix = BA07
| PubChem = 9690109
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 7962943
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = V63XWA605I
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03215
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201192

<!--Chemical data-->
| C=15 | H=15 | N=1 | O=2 | S=1 
| molecular_weight = 273.351
| smiles = O=S(C(c1ccccc1)c2ccccc2)CC(=O)N
| InChI = 1/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m1/s1
| InChIKey = YFGHCGITMMYXAQ-LJQANCHMBO
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YFGHCGITMMYXAQ-LJQANCHMSA-N
}}
{{medical}}
'''阿莫达非尼'''是由Celphalon制药公司研制的[[兴奋剂|兴奋剂]]药物，在2007年6月15日被FDA批准。<ref name="titleCDER Drug and Biologic Approvals for Calendar Year 2007">{{cite web| url= http://www.fda.gov/cder/rdmt/InternetNDA07.htm| title= CDER Drug and Biologic Approvals for Calendar Year 2007| accessdate= 2008-01-21| archiveurl= https://web.archive.org/web/20080223182730/http://www.fda.gov/cder/rdmt/InternetNDA07.htm| archivedate=2008-02-23| deadurl= yes}}</ref><ref name=ob>{{Citation |title=Search results from the "OB_Rx" table for query on "021875."
 |work=[[Approved_Drug_Products_with_Therapeutic_Equivalence_Evaluations|Orange Book]] |publisher=[[USFDA|USFDA]]
 |url=http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=021875&TABLE1=OB_Rx |accessdate=April 30, 2012
|date=March 2012}}</ref>阿莫达非尼是外消旋的药物[[莫达非尼|莫达非尼]]中具有活性成分的的(−)-(''R'')-对映异构物。

==参看==
*[[莫达非尼|莫达非尼]]

== 参考资料 ==
{{reflist|2}}

==外部链接==
*[http://www.nuvigil.com/ NUVIGIL.com - official site]
**[https://web.archive.org/web/20120512004005/http://www.nuvigil.com/media/Medication_Guide.pdf Medication Guide for Patients]
**[https://web.archive.org/web/20120726004059/http://nuvigil.com/media/Full_Prescribing_Information.pdf Full Prescribing Information]
*[http://www.ncbi.nlm.nih.gov/pubmed/22128728 "A single dose of armodafinil significantly promotes vigilance 11 hours post-dose"]
*[http://dl.dropbox.com/u/85192141/2009-darwish.pdf "Armodafinil and Modafinil Have Substantially Different Pharmacokinetic Profiles Despite Having the Same Terminal Half-Lives"]{{dead link|date=2018年5月 |bot=InternetArchiveBot |fix-attempted=yes }}, Darwish et al 2009

{{ADHD_pharmacotherapies}}
[[Category:神经递质|Category:神经递质]]
[[Category:分子神经学|Category:分子神经学]]
[[Category:神经科学|Category:神经科学]]
[[Category:作用機轉不明的藥物|Category:作用機轉不明的藥物]]
[[Category:世界反兴奋剂机构禁用物质|Category:世界反兴奋剂机构禁用物质]]